(NASDAQ: ENGN) Engene Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 61.98%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.85%.
Engene Holdings's earnings in 2026 is -$117,302,000.On average, 13 Wall Street analysts forecast ENGN's earnings for 2026 to be -$168,814,743, with the lowest ENGN earnings forecast at -$204,155,850, and the highest ENGN earnings forecast at -$138,557,771. On average, 13 Wall Street analysts forecast ENGN's earnings for 2027 to be -$149,436,080, with the lowest ENGN earnings forecast at -$192,996,205, and the highest ENGN earnings forecast at -$77,367,283.
In 2028, ENGN is forecast to generate -$62,858,406 in earnings, with the lowest earnings forecast at -$91,246,505 and the highest earnings forecast at $7,033,389.